Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Plos One|April 25, 2014
Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cellsSara Häggblad Sahlberg, Diana Spiegelberg, Bengt Glimelius, et al.
Frontiers in Oncology|May 28, 2026
Correction: Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespibAnja Charlotte Lundgren Mortensen, Tabassom Mohajershojai, Mehran Hariri, et al.
Frontiers in Oncology|October 26, 2020
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor OnalespibAnja Charlotte Lundgren Mortensen, Tabassom Mohajershojai, Mehran Hariri, et al.
International Journal of Oncology|April 17, 2018
Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapyAnja C Mortensen, Diana Spiegelberg, Anna-Karin Haylock, et al.
Journal of Pharmacological and Toxicological Methods|August 2, 2014
Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assayPavel Barta, Marie Volkova, Adrian Dascalu, et al.
International Journal of Oncology|September 1, 2011
The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell linesSara Häggblad Sahlberg, Diana Spiegelberg, Johan Lennartsson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2015
Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma modelDiana Spiegelberg, Anja C Mortensen, Ram K Selvaraju, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2025
Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapyFilipa Mendes, Samantha Y A Terry, Diana Spiegelberg, et al.
Frontiers in Oncology|October 17, 2019
The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer CellsAnja Charlotte Lundgren Mortensen, Diana Spiegelberg, Christopher John Brown, et al.
Scientific Reports|October 6, 2023
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancerAnja Charlotte Lundgren Mortensen, Hanna Berglund, Mehran Hariri, et al.
Pageof 4